Key Takeaways
- A quarter of two halves, with a cautious recovery underway: Q1 was weak, but Q2 improved, driven by commercial products and a shipment spillover from Q1, putting H1 results in line with mid-year expectations.
- Full-year guidance held, but Bavla site target cut: Management reaffirmed at least 8-9% revenue growth and 16-17% EBITDA margins for FY25, while lowering the Bavla site's current-year revenue estimate to ~INR300 crores from INR350 crores.
- The US election is the pivotal swing factor: Management sees the election's resolution as a catalyst to unlock delayed venture capital funding and CRAMS inquiries, with early, non-concrete signs of a pickup already visible.
- A multi-year margin recovery story is taking shape: H1 consolidated EBITDA margin was 14.3%, but a path to 25% in 2-3 years and eventually 30% is laid out, driven by a French turnaround, Indian normalization, and raw material tailwinds.
- What to watch next quarter: Whether the post-election pickup in CRAMS inquiries converts into concrete orders, the pace of the French facility's ramp-up toward breakeven, and any further adjustments to the Bavla site's growth trajectory.
Demand Environment & Market Recovery
- The funding freeze: A difficult market moment has been driven by venture capital firms delaying new biotech investments in the US, causing a slight slowdown in capturing new business, particularly in development projects.
- The election catalyst: Management's core thesis is that the resolution of the US election removes uncertainty, and they have already seen "some things starting to change" in CRAMS inquiries from the week after the vote, though nothing is concrete yet.
- Biosecure Act tailwind is modest so far: Inquiries related to the proposed Biosecure bill are up only about 10-15% on top of existing levels, not a doubling, and the company is waiting to see the new administration's strategy toward China before factoring in a larger benefit.
- Client M&A risk is an unknown: When asked about the impact of biotech clients being acquired by larger companies on the pipeline, management declined to comment, stating they will only know the effect once deals are done.
Villemagne: "Now they know, so now they act. That's so it for CRAMs. We have seen very quickly some things starting to change from last week. Nothing concrete yet, of course. It's a bit new, but we have been seeing that now the election is done, that's going to really move forward and especially from a venture capital perspectives, reinforce some of our customers that they were looking for an additional table to come out."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Carbogen Amcis | ▲ Improving | Q1 was weak, but Q2 was better, driven by high commercial product revenue and a CHF0.98 crore shipment spillover from Q1; on track to match the ~CHF25.5 crore budget for the year. |
| India CRAMS | ▲ Strong growth | Revenue grew 37% on the back of regulatory clearances received, leading to an increased order book from existing and potentially new customers. |
| Cholesterol & Vitamin D | ▼ Revenue, ▲ Margin | Revenue declined YoY due to lower cholesterol asset sales and a post-COVID slowdown in vitamin D consumption, but margin improved to 14.7% from 10% due to a better product mix. |
| India Quats & Generics | ▼ Soft | Revenue declined due to an agrochemical industry slowdown; a pickup is expected from the beginning of the new calendar year, with full-year revenue of INR80-90 crores at 6-7% margins. |
| French Facility | ▬ Ramping | Challenges are resolved and the facility is fully validated, but not yet running at full capacity; H2 revenue is expected at ~€0.6 crore with an EBITDA loss of ~€0.15 crore. |
Margins: The Recovery Path
- H1 pressure points: Consolidated EBITDA margin was 14.3% in H1, weighed down by adverse Swiss franc FX movement on employee expenses, a higher cost of goods sold due to a larger commercial revenue mix, and an underperforming Dutch facility.
- The H2 bridge: Full-year margins are expected to improve from the H1 level as revenues increase in Q3 and Q4, with the benefit of reduced wool grease prices starting to accrue from January, making more cholesterol products profitable.
- The 2-3 year ambition: Management's goal is to reach a 25% EBITDA margin over the next 2-3 years, driven by the French entity reaching breakeven and turning positive, India normalizing to historical margins above 30%, and Dutch margins improving with lower raw material costs.
Dalal: "So that is the goal for the next 2 years to 3 years, that is where we want to get at, and then we could move towards the 30% margin."
Pipeline & Portfolio Dynamics
- Late-stage is the focus: Management declined to disclose the total number of molecules by phase or their movement, stating that the most important number is the late Phase III and commercial molecules, as early phases have a huge dropout rate.
- One molecule stands out: While refusing to size individual assets, management volunteered that one late-stage molecule in the portfolio has "extremely good and very promising" clinical trials and is "very, very likely to happen," though they cautioned that predicting commercial success is notoriously difficult.
- ADC positioning is incomplete: The company offers three of four elements of the ADC value chain (payload/linker, conjugation, fill and finish) but lacks the antibody capability, which would require major acquisitions to add in the coming years.
Villemagne: "In my 25 years of experience in that industry, it's very often the marketing figures that was provided. We are not totally right. So there was always either a overestimation, very often an overestimation. And sometimes, yes, an underestimation. But it's almost an impossible to predict, which molecule is going to happen."
Operational & Strategic Updates
- French facility lands a win: A new contract with a German customer worth more than €0.1 crore was booked two days before the call, bringing the total order book for that facility above €1 crore.
- Cross-entity collaboration increasing: More projects are being transferred directly from Carbogen Amcis to the Indian facility or are in discussion for production in the coming months, a sign of growing internal synergy.
- Digitalization milestone achieved: A technical go-live for new lab management and quality deviation tools has been completed, with the operational go-live of SAP targeted for the new fiscal year starting April 1st.
- A major customer investment in sight: The company is in discussions with a specific customer to invest a "2-digit million" amount in another facility to debottleneck the supply chain for future demand.
Villemagne: "And we are engaging new discussion with that specific customer to further invest in another facility to debottleneck the supply chain for the future as well and we are speaking about a 2-digit million investment in that particular facility."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | At least 8% to 9% | FY25 |
| Full-year consolidated EBITDA margin | At least 16% to 17% | FY25 |
| Carbogen Amcis revenue | Match budget target of ~CHF 25.5 crore | FY25 |
| Bavla site revenue | ~INR 300 crores (revised from INR 350 crores) | FY25 |
| Bavla site growth | 25% to 30% growth | FY26 |
| Net debt reduction | Decrease to CHF 15-16 crore from CHF 17.3 crore | By March '25 |
| Net debt-to-EBITDA ratio | Below 2x | Next 2 to 2.5 financial years |
| Net debt-to-EBITDA ratio | Between 1.5x to 2x | By FY27 |
| Consolidated EBITDA margin | Reach 25%, then move toward 30% | Next 2 to 3 years |
| French facility EBITDA loss | Narrow to ~€0.15 crore | H2 FY25 |
| India Quats & Generics pickup | Recovery to begin | Beginning of new calendar year |
| Wool grease price benefit | Reduced raw material costs to accrue | From January (Q4 FY25) |
| SAP operational go-live | New fiscal year '25 | From April 1st |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹789 cr, +35% YoY from ₹586 cr in Q2 FY24 |
| Cost of goods sold | ~24% of revenue, vs historical average of ~20% due to higher commercial revenue share |
| Employee expenses | ~₹320 cr, in line with Q1 FY25 |
| Other expenses | ~₹130 cr, including notional FX loss |
| EBITDA | ₹148 cr, one of the highest in company history |
| Profit before tax | ₹42 cr |
| Tax expense | ~₹9 cr, ~20-22% of PBT |
| PAT | ₹33 cr, PAT margin of 4.2% |
| Full-year revenue growth guidance | At least 8% to 9% |
| Full-year consolidated EBITDA margin guidance | At least 16% |
| Carbogen Amcis CRAMS revenue | ₹663 cr, +52% YoY from ₹437 cr in Q2 FY24 |
| Carbogen Amcis CRAMS EBITDA margin | ~20%, vs 12.2% in Q2 FY24 |
| Cholesterol and Vitamin D analogues revenue | ₹55 cr, vs ₹86 cr in Q2 FY24 |
| Cholesterol and Vitamin D analogues EBITDA margin | 14.7%, vs 10% in Q2 FY24 |
| India CRAMS revenue | ₹49 cr, +37% YoY from ₹36 cr in Q2 FY24 |
| India CRAMS EBITDA margin | ~14% |
| India Quats and Generic revenue | ₹21 cr, vs ₹27 cr in Q2 FY24 |
| India Quats and Generic EBITDA margin | ~7% |
| Net debt | CHF 17.3 cr as of 30 Sep, vs CHF 16.2 cr as of Mar FY24 |
| Net debt expected as of March FY25 | CHF 15 cr to CHF 16 cr |
| Net debt-to-EBITDA target | 1.5 to 2 by FY27 |
| Total CapEx H1 FY25 | ~₹125 cr; full year expected ~₹250 cr |
| Carbogen Amcis order book | ~CHF 11 cr as of 30 Sep, down from CHF 14.2 cr |
| Carbogen Amcis FY25 budget target | CHF 25.5 cr |
| French facility H1 FY25 revenue | €0.35 cr; EBITDA loss of €0.4 cr |
| French facility H2 FY25 expected revenue | €0.6 cr; expected EBITDA loss of €0.15 cr |
| Bavla site FY25 revenue expected | Closer to ~₹300 cr, vs earlier guidance of ₹350 cr |
| Bavla site next FY growth expectation | 25% to 30% |
| Quats and Generics FY25 revenue expected | ~₹80 cr to ₹90 cr |
| Revenue spillover from Q1 to Q2 | CHF 0.98 cr |
| Long-term EBITDA margin target | 25% over next 2-3 years, eventually moving towards 30% |